Scarica l'app Stockscreener
252.34
3.39%
8.2325
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
Is AbbVie (NYSE:ABBV) Fully Valued After Tepkinly? - Kalkine Media
AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send? - TradingKey
Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF - The Motley Fool
Is AbbVie (ABBV) Fully Priced Despite Tepkinly Approval And Cash Flow? - simplywall.st
AHA urges court to reject AbbVie bid to change 340B program rules - EIN News
AbbVie stock holds steady as its diversified portfolio underpins long-term growth - Ad Hoc News
ABBV Maintained by Citigroup -- Price Target Raised to $260 - GuruFocus
Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise? - TradingView
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap - Yahoo Finance
Nxera Pharma Webinar for Financial Results Presentation - GlobeNewswire Inc.
Red day on Tuesday for AbbVie stock after losing 1.31% - StockInvest.us
AbbVie (ABBV) Stock Looks Fully Priced After A 152% Run - Yahoo Finance
AbbVie Tokenized Stock price today, ABBVX to USD chart, marketcap and volume - CryptoSlate
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie (ABBV) Faces Seventh Consecutive Loss Amid Mixed Sentimen - GuruFocus
AbbVie extends slide to a seventh straight session - MSN
AbbVie price seeks a supportive bottomForecast today14-07-2026 - Economies.com
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic? - Yahoo! Finance Canada
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development - Investing News Network
AbbVie stock: Is ABBV outperforming the healthcare sector? - MSN
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb - The Globe and Mail
AbbVie pharmaceutical project moves forward in Durham: 'Huge deal' - ABC11 News
Apogee Therapeutics (NASDAQ: APGE) backs AbbVie’s $135.11‑per‑share all‑cash deal - Stock Titan
ABBV Maintained by UBS -- Price Target Raised to $260 - GuruFocus
BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating - marketscreener.com
ABBV Maintained by BMO Capital -- Price Target Raised to $300 - GuruFocus
UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating - marketscreener.com
Why is AbbVie stock climbing today? By Investing.com - Investing.com Canada
BMO raises Abbvie stock price target to $300 on Skyrizi strength - Investing.com
AbbVie stock holds steady on its antibody and immunology franchise - ad-hoc-news.de
AbbVie Employees Across Asia Unite Through Week of Possibilities by Serving and Supporting Communities - PR Newswire
AbbVie stock holds steady after a new U.S. market backdrop - ad-hoc-news.de
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Eli Lilly & Co (LLY) - The Globe and Mail
BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $276 - Moomoo
AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Sco - GuruFocus
West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business - Yahoo Finance
ABBV Maintained by B of A Securities -- Price Target Raised to $276 - GuruFocus
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner - AOL.com
AbbVie Inc. Stock 12‑Month Price Target Raised to $263.72, Implies 6% Upside - TradingView
Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands - Investorideas.com
ABBV Maintains Overweight Rating -- Price Target Raised to $295 - GuruFocus
BofA Securities Adjusts AbbVie Price Target to $276 From $234 - marketscreener.com
ABBV Maintained by RBC Capital -- Price Target Raises to $260 - GuruFocus
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $276 to $295 - Moomoo
AbbVie's Q2 Results Expected to be Inline With Expectations, RBC Says - marketscreener.com
Dividend Roundup: Costco, Phillips 66, Abbott Labs, AbbVie, and more (DVY:NASDAQ) - Seeking Alpha
RBC Raises Price Target on AbbVie to $280 From $260, Keeps Outperform Rating - marketscreener.com
Wells Fargo Adjusts Price Target on AbbVie to $295 From $260 - marketscreener.com
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
AbbVie (NYSE:ABBV): Dividend Stability Under The Spotlight - Kalkine Media
JPMorgan Adjusts Price Target on AbbVie to $280 From $260 - marketscreener.com
ABBV Maintains Buy Rating -- Price Target Raised to $261 - GuruFocus
ABBV Maintained by JP Morgan -- Price Target Raised to $280 - GuruFocus
ABBV Leads Its Peer Group. You Pay For That - Trefis
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth - TradingView
Guggenheim raises Abbvie stock price target to $261 on Rinvoq strength - Investing.com
AbbVie stock trades steadily as investors weigh immunology and oncology pipeline - AD HOC NEWS
Guggenheim Adjusts Price Target on AbbVie to $261 From $249 - marketscreener.com
AbbVie Acquires Apogee to Maintain Dividend King Status - Intellectia AI
AbbVie Stock Traded Its Old Story for New Growth. Here Is The Price. - Trefis
3.71%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):